Oncodia closed a post-seed round

August 31, 2020

During August Oncodia raised 3.3MSEK capital in a private investment round. The company was supported by the existing owners and attracted new investors. We would like to welcome Linnéa Capital on-board as a new shareholder.

Oncodia closed a post-seed round

More from our blog

On 28th-29th of April, Oncodia will proudly present the company portfolio at the Nordic Precision Medicine Forum in Stockholm and at the same time participate in the 12th NACG workshop in Reykjavik, Iceland.

ALTOmate v.2 targets to cover ion semiconductor sequencing space

ALTOmate v.1.2.1 is released on schedule to improve selectivity in regions with poor alignment

Oncodia released a scheduled update of VARify to v.1.1.0

ALTOmate v.1.2.0 was released on schedule to increase mutation sensitivity and enhance the sequencing data preprocessing

Oncodia attracts a round of private investment

ALTOmate v.1.1.0 was released on schedule to meet user demands

Oncodia adds VARify to the precision medicine toolbox

“Oncodia's Basic Test” for better molecular diagnostics!

Development of ALTOmate follows the plan with a scheduled update and release of version 1.0.1

As a producer and developer, Oncodia is the natural sales partner of NGEx products in Scandinavia

Oncodia’s product portfolio expands with CE/IVD software for mutational diagnostics

Oncodia closed a post-seed round

Oncodia AB has moved to new premises

Oncodia expands offering to include DNA and RNA extraction for molecular pathology

Oncodia wins EuroStars grant

Oncodia is officially an UIC Business Accelerator company

Quality management system implemented

Horizon 2020 SME Instrument grant awarded

Oncodia secures exclusive, worldwide license to key technology

Senior medical device expertise to the board of Oncodia

EIT Health Headstart grant recipient

Oncodia closes Seed Round of MSEK 4